noom glp-1 companion program Launches Microdosing for Longevity GLP-1 Companion | Digital Health

Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule

Victoza (Liraglutide) is approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of three major adverse cardiovascular events

Given this dilemma, shifting focus to alternative weight loss therapies that do not rely on the leptin-melanocortin system - such as GLP-1 RAs, which have distinctly different mechanisms of action - may offer theoretical feasibility for the treatment of MC4R -deficient obesity

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual agonist tirzepatide carry the evidence: STEP for semaglutide (NEJM 2021), SURMOUNT for tirzepatide (NEJM 2022), and SURMOUNT-OSA for tirzepatide in obstructive sleep apnea (NEJM 2024)